ticlopidine has been researched along with Obesity in 21 studies
Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.
Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
| Excerpt | Relevance | Reference |
|---|---|---|
| " The aim of this prospective, randomised, study was to compare the PD effects of standard-dose prasugrel [60 mg loading dose (LD)/10 mg daily maintenance dose (MD)] with high-dose clopidogrel (900 mg LD/150 mg daily MD) in non-diabetic obese [body mass index (BMI) ≥30 kg/m²] patients, with coronary artery disease (CAD) on aspirin therapy." | 9.19 | Pharmacodynamic effects of standard dose prasugrel versus high dose clopidogrel in non-diabetic obese patients with coronary artery disease. ( Angiolillo, DJ; Bass, TA; Darlington, A; Desai, B; Ferreiro, JL; Guzman, LA; Patel, R; Rollini, F; Tello-Montoliu, A; Ueno, M, 2014) |
| "A number of reports have demonstrated that obesity is a risk factor for a reduced clopidogrel pharmacodynamic response." | 8.95 | Obesity and Inflammation and Altered Clopidogrel Pharmacokinetics and Pharmacodynamics. ( Monte, SV; Norgard, NB, 2017) |
| "Overweight or obese patients exhibit poorer platelet responses to clopidogrel." | 8.12 | Is platelet responsiveness to clopidogrel attenuated in overweight or obese patients and why? A reverse translational study in mice. ( Ge, PX; Ji, JZ; Jiang, LP; Li, YF; Mi, QY; Tai, T; Xie, HG; Zhu, T, 2022) |
| " Leptin is the obesity gene product, and its serum level increases with obesity." | 7.83 | Effect of obesity and serum leptin level on clopidogrel resistance. ( Çiftçi, C; Doğan, A; Görmüş, U; Kahraman, S; Özdemir, E; Usta, E, 2016) |
| "This study aimed to analyze the impact of body mass index (BMI) and the metabolic syndrome (MS) on responses to clopidogrel or prasugrel and bleeding risk after acute coronary syndrome." | 7.80 | Impact of obesity and the metabolic syndrome on response to clopidogrel or prasugrel and bleeding risk in patients treated after coronary stenting. ( Alessi, MC; Bonnet, G; Bonnet, JL; Cuisset, T; Deharo, P; Dutour, A; Gaborit, B; Lambert, M; Loundou, AD; Morange, PE; Pankert, M; Quilici, J; Valéro, R; Verdier, V, 2014) |
| "Obesity is a cluster of medical conditions affecting several pathophysiological processes, including platelet (PLT) function." | 5.42 | Obesity and antiplatelet effects of acetylsalicylic acid and clopidogrel in patients with stable angina pectoris after percutaneous coronary intervention. ( Gąsior, Z; Haberka, M; Kyrcz-Krzemień, S; Lasota, B; Mizia-Stec, K, 2015) |
| "Obesity is associated with a prothrombotic state resulting from increased thrombin generation, platelet hyper-reactivity, and decreased fibrinolysis." | 5.39 | Obesity is associated with poor response to clopidogrel and an increased susceptibility to protease activated receptor-1 mediated platelet activation. ( Gremmel, T; Kopp, CW; Koppensteiner, R; Panzer, S; Seidinger, D; Steiner, S, 2013) |
| " The aim of this prospective, randomised, study was to compare the PD effects of standard-dose prasugrel [60 mg loading dose (LD)/10 mg daily maintenance dose (MD)] with high-dose clopidogrel (900 mg LD/150 mg daily MD) in non-diabetic obese [body mass index (BMI) ≥30 kg/m²] patients, with coronary artery disease (CAD) on aspirin therapy." | 5.19 | Pharmacodynamic effects of standard dose prasugrel versus high dose clopidogrel in non-diabetic obese patients with coronary artery disease. ( Angiolillo, DJ; Bass, TA; Darlington, A; Desai, B; Ferreiro, JL; Guzman, LA; Patel, R; Rollini, F; Tello-Montoliu, A; Ueno, M, 2014) |
| "A number of reports have demonstrated that obesity is a risk factor for a reduced clopidogrel pharmacodynamic response." | 4.95 | Obesity and Inflammation and Altered Clopidogrel Pharmacokinetics and Pharmacodynamics. ( Monte, SV; Norgard, NB, 2017) |
| "Overweight or obese patients exhibit poorer platelet responses to clopidogrel." | 4.12 | Is platelet responsiveness to clopidogrel attenuated in overweight or obese patients and why? A reverse translational study in mice. ( Ge, PX; Ji, JZ; Jiang, LP; Li, YF; Mi, QY; Tai, T; Xie, HG; Zhu, T, 2022) |
| " Leptin is the obesity gene product, and its serum level increases with obesity." | 3.83 | Effect of obesity and serum leptin level on clopidogrel resistance. ( Çiftçi, C; Doğan, A; Görmüş, U; Kahraman, S; Özdemir, E; Usta, E, 2016) |
| "This study aimed to analyze the impact of body mass index (BMI) and the metabolic syndrome (MS) on responses to clopidogrel or prasugrel and bleeding risk after acute coronary syndrome." | 3.80 | Impact of obesity and the metabolic syndrome on response to clopidogrel or prasugrel and bleeding risk in patients treated after coronary stenting. ( Alessi, MC; Bonnet, G; Bonnet, JL; Cuisset, T; Deharo, P; Dutour, A; Gaborit, B; Lambert, M; Loundou, AD; Morange, PE; Pankert, M; Quilici, J; Valéro, R; Verdier, V, 2014) |
| " Major adverse cardiovascular events, stent thrombosis, target lesion revascularization (TLR), target vessel revascularization, and bleeding events were analyzed after 1-year follow-up." | 2.78 | Efficacy and safety of triple antiplatelet therapy in obese patients undergoing stent implantation. ( Gao, W; Ge, H; Guo, Y; Zhang, Q; Zhou, Z, 2013) |
| " (2) Clopidogrel may be under dosed in obese patients." | 2.75 | Clopidogrel affects leukocyte dependent platelet aggregation by P2Y12 expressing leukocytes. ( Bode, C; Diehl, P; Halscheid, C; Helbing, T; Moser, M; Olivier, C, 2010) |
| "High interindividual variability in clinical outcomes following clopidogrel's standard dosing regimen continues to be a challenge even two decades after its approval." | 1.46 | Identifying clinically relevant sources of variability: The clopidogrel challenge. ( Horenstein, RB; Jiang, XL; Lesko, LJ; Lewis, JP; Peletier, LA; Samant, S; Schmidt, S; Shuldiner, AR, 2017) |
| "Obesity is a cluster of medical conditions affecting several pathophysiological processes, including platelet (PLT) function." | 1.42 | Obesity and antiplatelet effects of acetylsalicylic acid and clopidogrel in patients with stable angina pectoris after percutaneous coronary intervention. ( Gąsior, Z; Haberka, M; Kyrcz-Krzemień, S; Lasota, B; Mizia-Stec, K, 2015) |
| "Obesity is associated with a prothrombotic state resulting from increased thrombin generation, platelet hyper-reactivity, and decreased fibrinolysis." | 1.39 | Obesity is associated with poor response to clopidogrel and an increased susceptibility to protease activated receptor-1 mediated platelet activation. ( Gremmel, T; Kopp, CW; Koppensteiner, R; Panzer, S; Seidinger, D; Steiner, S, 2013) |
| "Although obesity is a known risk factor for coronary artery disease, its impact on the presentation, treatment, and outcome of patients with acute coronary syndromes (ACS) has not been well studied." | 1.33 | The obesity paradox in non-ST-segment elevation acute coronary syndromes: results from the Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the American College of Cardiology/American Heart A ( Boden, WE; Diercks, DB; Gibler, WB; Kirk, JD; Mulgund, J; Ohman, EM; Peterson, ED; Pollack, CV; Roe, MT; Smith, SC, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (19.05) | 29.6817 |
| 2010's | 15 (71.43) | 24.3611 |
| 2020's | 2 (9.52) | 2.80 |
| Authors | Studies |
|---|---|
| Puccini, M | 1 |
| Rauch, C | 1 |
| Jakobs, K | 1 |
| Friebel, J | 1 |
| Hassanein, A | 1 |
| Landmesser, U | 1 |
| Rauch, U | 1 |
| Jiang, LP | 1 |
| Ji, JZ | 1 |
| Ge, PX | 1 |
| Zhu, T | 1 |
| Mi, QY | 1 |
| Tai, T | 1 |
| Li, YF | 1 |
| Xie, HG | 1 |
| Darlington, A | 1 |
| Tello-Montoliu, A | 1 |
| Rollini, F | 1 |
| Ueno, M | 1 |
| Ferreiro, JL | 1 |
| Patel, R | 1 |
| Desai, B | 1 |
| Guzman, LA | 1 |
| Bass, TA | 1 |
| Angiolillo, DJ | 1 |
| Pankert, M | 1 |
| Quilici, J | 1 |
| Loundou, AD | 1 |
| Verdier, V | 1 |
| Lambert, M | 1 |
| Deharo, P | 1 |
| Bonnet, G | 1 |
| Gaborit, B | 1 |
| Morange, PE | 1 |
| Valéro, R | 1 |
| Dutour, A | 1 |
| Bonnet, JL | 1 |
| Alessi, MC | 1 |
| Cuisset, T | 1 |
| Daels, FP | 1 |
| Gaizauskas, A | 1 |
| Rioja, J | 1 |
| Varshney, AK | 1 |
| Erkan, E | 1 |
| Ozgok, Y | 1 |
| Melekos, M | 1 |
| de la Rosette, JJ | 1 |
| Siasos, G | 1 |
| Oikonomou, E | 1 |
| Zaromitidou, M | 1 |
| Kioufis, S | 1 |
| Kokkou, E | 1 |
| Mourouzis, K | 1 |
| Vlasis, K | 1 |
| Vavuranakis, M | 1 |
| Stone, PH | 1 |
| Papavassiliou, AG | 1 |
| Tousoulis, D | 1 |
| Beavers, CJ | 1 |
| Heron, P | 1 |
| Smyth, SS | 1 |
| Bain, JA | 1 |
| Macaulay, TE | 1 |
| Haberka, M | 1 |
| Mizia-Stec, K | 1 |
| Lasota, B | 1 |
| Kyrcz-Krzemień, S | 1 |
| Gąsior, Z | 1 |
| Legrand, D | 1 |
| Barbato, E | 1 |
| Chenu, P | 1 |
| Magne, J | 1 |
| Vrolix, M | 1 |
| Wijns, W | 1 |
| Legrand, V | 1 |
| Samant, S | 1 |
| Jiang, XL | 1 |
| Peletier, LA | 1 |
| Shuldiner, AR | 1 |
| Horenstein, RB | 1 |
| Lewis, JP | 1 |
| Lesko, LJ | 1 |
| Schmidt, S | 1 |
| Karadağ, B | 1 |
| Doğan, A | 1 |
| Kahraman, S | 1 |
| Usta, E | 1 |
| Özdemir, E | 1 |
| Görmüş, U | 1 |
| Çiftçi, C | 1 |
| Norgard, NB | 1 |
| Monte, SV | 1 |
| Wang, ZJ | 1 |
| Zhou, YJ | 1 |
| Liu, YY | 1 |
| Yu, M | 1 |
| Shi, DM | 1 |
| Zhao, YX | 1 |
| Guo, YH | 1 |
| Cheng, WJ | 1 |
| Nie, B | 1 |
| Ge, HL | 1 |
| Jia, DA | 1 |
| Yang, SW | 1 |
| Yan, ZX | 1 |
| Diehl, P | 1 |
| Olivier, C | 1 |
| Halscheid, C | 1 |
| Helbing, T | 1 |
| Bode, C | 1 |
| Moser, M | 1 |
| Scholl, S | 1 |
| Dellon, ES | 1 |
| Shaheen, NJ | 1 |
| Gremmel, T | 1 |
| Steiner, S | 1 |
| Seidinger, D | 1 |
| Koppensteiner, R | 1 |
| Panzer, S | 1 |
| Kopp, CW | 1 |
| Gao, W | 1 |
| Zhang, Q | 1 |
| Ge, H | 1 |
| Guo, Y | 1 |
| Zhou, Z | 1 |
| Patel, MR | 1 |
| Peterson, ED | 2 |
| Schaerlig, E | 1 |
| Diercks, DB | 1 |
| Roe, MT | 1 |
| Mulgund, J | 1 |
| Pollack, CV | 1 |
| Kirk, JD | 1 |
| Gibler, WB | 1 |
| Ohman, EM | 1 |
| Smith, SC | 1 |
| Boden, WE | 1 |
2 reviews available for ticlopidine and Obesity
| Article | Year |
|---|---|
Obesity and Antiplatelets-Does One Size Fit All?
Topics: Clopidogrel; Drug Therapy, Combination; Humans; Obesity; Platelet Aggregation Inhibitors; Ticlopidin | 2015 |
Obesity and Inflammation and Altered Clopidogrel Pharmacokinetics and Pharmacodynamics.
Topics: Cardiovascular Diseases; Clopidogrel; Humans; Inflammation; Obesity; Platelet Aggregation Inhibitors | 2017 |
4 trials available for ticlopidine and Obesity
| Article | Year |
|---|---|
Pharmacodynamic effects of standard dose prasugrel versus high dose clopidogrel in non-diabetic obese patients with coronary artery disease.
Topics: Aspirin; Biomarkers; Blood Platelets; Body Mass Index; Cell Adhesion Molecules; Clopidogrel; Coronar | 2014 |
The STIB score: a simple clinical test to predict clopidogrel resistance.
Topics: Aged; Angina, Stable; Angioplasty, Balloon, Coronary; Belgium; Biomarkers; Blood Platelets; Body Mas | 2015 |
Clopidogrel affects leukocyte dependent platelet aggregation by P2Y12 expressing leukocytes.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Thromb | 2010 |
Efficacy and safety of triple antiplatelet therapy in obese patients undergoing stent implantation.
Topics: Adult; Aged; Aspirin; Blood Platelets; Cilostazol; Clopidogrel; Drug Therapy, Combination; Female; H | 2013 |
15 other studies available for ticlopidine and Obesity
| Article | Year |
|---|---|
Being Overweight or Obese Is Associated with an Increased Platelet Reactivity Despite Dual Antiplatelet Therapy with Aspirin and Clopidogrel.
Topics: Adenosine; Adenosine Diphosphate; Aspirin; Blood Platelets; Clopidogrel; Humans; Obesity; Overweight | 2023 |
Is platelet responsiveness to clopidogrel attenuated in overweight or obese patients and why? A reverse translational study in mice.
Topics: Animals; Blood Platelets; Clopidogrel; Humans; Mice; Obesity; Overweight; Platelet Aggregation; Plat | 2022 |
Impact of obesity and the metabolic syndrome on response to clopidogrel or prasugrel and bleeding risk in patients treated after coronary stenting.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Female; Humans; Incidence; Male; Metabolic Syndrome; Mid | 2014 |
Age-related prevalence of diabetes mellitus, cardiovascular disease and anticoagulation therapy use in a urolithiasis population and their effect on outcomes: the Clinical Research Office of the Endourological Society Ureteroscopy Global Study.
Topics: Adolescent; Adult; Age Distribution; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Cardiovascula | 2015 |
Clopidogrel response variability is associated with endothelial dysfunction in coronary artery disease patients receiving dual antiplatelet therapy.
Topics: Activation, Metabolic; Aged; Aspirin; Brachial Artery; Clopidogrel; Coronary Disease; Cytochrome P-4 | 2015 |
Obesity and antiplatelet effects of acetylsalicylic acid and clopidogrel in patients with stable angina pectoris after percutaneous coronary intervention.
Topics: Aged; Angina, Stable; Aspirin; Clopidogrel; Female; Humans; Male; Middle Aged; Obesity; Percutaneous | 2015 |
Identifying clinically relevant sources of variability: The clopidogrel challenge.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Aging; Body Mass Index; Clopidogrel; Computer Simulatio | 2017 |
Obesity, leptin, and thrombosis: Focus on clopidogrel resistance.
Topics: Animals; Biomedical Research; Clopidogrel; Drug Resistance; Humans; Leptin; Mice; Obesity; Thrombosi | 2016 |
Effect of obesity and serum leptin level on clopidogrel resistance.
Topics: Aged; Clopidogrel; Cohort Studies; Drug Resistance; Female; Humans; Leptin; Male; Middle Aged; Obesi | 2016 |
Obesity and cardiovascular thrombotic events in patients undergoing percutaneous coronary intervention with drug-eluting stents.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Blood Vessel Prosthesis; Body Mass Index; Clopidogrel; Coro | 2009 |
Treatment of GERD and proton pump inhibitor use in the elderly: practical approaches and frequently asked questions.
Topics: Adenocarcinoma; Adult; Age Distribution; Age Factors; Aged; Aged, 80 and over; Aspirin; Barrett Esop | 2011 |
Obesity is associated with poor response to clopidogrel and an increased susceptibility to protease activated receptor-1 mediated platelet activation.
Topics: Adenosine Diphosphate; Aged; Angioplasty; Blood Platelets; Case-Control Studies; Cell Adhesion Molec | 2013 |
Clopidogrel dosing in overweight patients: does one size fit all?
Topics: Blood Vessel Prosthesis Implantation; Body Mass Index; Body Weight; Clopidogrel; Coronary Stenosis; | 2004 |
[Highlights from the American College of Cardiology Annual Scientific Session 2005: March 5-9, 2005, Orlando, Florida].
Topics: Aspirin; Cardiovascular Diseases; Cholesterol, LDL; Clopidogrel; Humans; Hypercholesterolemia; Obesi | 2005 |
The obesity paradox in non-ST-segment elevation acute coronary syndromes: results from the Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the American College of Cardiology/American Heart A
Topics: Aged; Angina, Unstable; Body Mass Index; Clopidogrel; Female; Guideline Adherence; Humans; Hypolipid | 2006 |